Elisabeth Sandoval Net Worth

Elisabeth Sandoval biography

Elisabeth A. Sandoval serves as Independent Director of the Company. Ms. Sandoval currently serves as the Chief Commercial Officer and Executive Vice President of Corporate Strategy of Alder Biopharmaceuticals, a public biopharmaceutical company, with primary responsibility for leading and developing commercial strategy, capabilities and execution. Ms. Sandoval is also responsible for developing and leading medical affairs, investor relations, corporate communications and business development functions. Before joining Alder, Ms. Sandoval was Chief Commercial Officer for Kythera Biopharmaceuticals, a public biopharmaceutical company, where she led the commercial strategy and execution including the hiring and development of all commercial functions and launch of a first-in-class product prior to Kythera’s acquisition by Allergan. Before Kythera, Ms. Sandoval was Vice President of Marketing for Bausch and Lomb Surgical. Prior to this position, Ms. Sandoval was Vice President of Global Marketing at Allergan. Ms. Sandoval also serves on the board of directors for Alastin Skincare, a privately held company. Ms. Sandoval began her career in research and development at Johnson & Johnson’s Ethicon division. She holds an MBA from Pepperdine University and a B.S. in Biology from the University of California, Irvine.

What is the salary of Elisabeth Sandoval?

As the Independent Director of Menlo Therapeutics, the total compensation of Elisabeth Sandoval at Menlo Therapeutics is $259,507. There are no executives at Menlo Therapeutics getting paid more.

How old is Elisabeth Sandoval?

Elisabeth Sandoval is 58, she's been the Independent Director of Menlo Therapeutics since 2019. There are 4 older and 5 younger executives at Menlo Therapeutics. The oldest executive at Menlo Therapeutics, Inc. is Rex Bright, 79, who is the Director.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr e Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer